5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.41▲ | 2.41▲ | 2.41▲ | 2.42▲ | 2.58▼ |
MA10 | 2.40▲ | 2.41▲ | 2.40▲ | 2.48▼ | 2.65▼ |
MA20 | 2.41▲ | 2.38▲ | 2.37▲ | 2.59▼ | 2.80▼ |
MA50 | 2.40▲ | 2.40▲ | 2.44▼ | 2.74▼ | 3.94▼ |
MA100 | 2.35▲ | 2.45▼ | 2.54▼ | 2.85▼ | 5.24▼ |
MA200 | 2.40▲ | 2.56▼ | 2.61▼ | 3.66▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.001▲ | 0.006▲ | 0.013▲ | -0.015▼ | 0.046▲ |
RSI | 55.615▲ | 54.545▲ | 51.604▲ | 40.387▼ | 38.055▼ |
STOCH | 45.139 | 62.103 | 86.941▲ | 22.195 | 19.404▼ |
WILL %R | -37.500 | -21.429▲ | -6.818▲ | -61.017 | -82.707▼ |
CCI | 64.167 | 42.000 | 63.451 | -92.985 | -139.942▼ |
Monday, September 08, 2025 08:00 AM
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) released new data at the HRX Live 2025 Meeting in Atlanta showing that its atrioventricular interval modulation (AVIM) therapy produces ...
|
Thursday, September 04, 2025 02:15 PM
Results from long-term follow up of patients treated with atrioventricular interval modulation (“AVIM”) therapy show blood pressure-lowering ...
|
Thursday, September 04, 2025 02:15 PM
Results from long-term follow up of patients treated with atrioventricular interval modulation (“AVIM”) therapy show blood pressure-lowering ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
25/09/25 | 2.41 | 2.43 | 2.34 | 2.43 | 235,870 |
24/09/25 | 2.35 | 2.45 | 2.20 | 2.42 | 461,919 |
23/09/25 | 2.47 | 2.48 | 2.33 | 2.35 | 232,947 |
22/09/25 | 2.44 | 2.54 | 2.42 | 2.45 | 290,710 |
19/09/25 | 2.50 | 2.52 | 2.42 | 2.44 | 551,840 |
18/09/25 | 2.50 | 2.54 | 2.46 | 2.51 | 95,702 |
17/09/25 | 2.54 | 2.57 | 2.45 | 2.46 | 152,048 |
16/09/25 | 2.60 | 2.63 | 2.50 | 2.53 | 213,328 |
15/09/25 | 2.58 | 2.68 | 2.5437 | 2.60 | 224,869 |
12/09/25 | 2.62 | 2.6567 | 2.56 | 2.57 | 119,272 |
|
|
||||
|
|
||||
|
|